Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07211386 · ClinicalTrials.gov registry record · NA
The Erector Spinae Plane Block For Gastrointestinal Malignancy Pain Treatment (EGIPT)
A NA study of Pain Control and Gastrointestinal Malignancy, sponsored by Abramson Cancer Center at Penn Medicine.
- Recruiting
- Registry status
- NA
- Development phase
- 25
- Enrollment target
- 4
- Study locations
NCT07211386: Recruiting NA study of Pain Control and Gastrointestinal Malignancy, sponsored by Abramson Cancer Center at Penn Medicine.
NCT07211386 is a NA study of Pain Control and Gastrointestinal Malignancy that is actively recruiting participants, run by Abramson Cancer Center at Penn Medicine. The registered enrollment target is 25 participants, below the 43-participant average among 3 other Pain Control trials with a reported enrollment target (42% lower). The trial reports 4 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07211386, a NA study of Pain Control and Gastrointestinal Malignancy, is actively recruiting participants, sponsored by Abramson Cancer Center at Penn Medicine.
- RECRUITING
- Registry status
- NA
- Development phase
- 25 participants
- Enrollment target
- 4
- Study locations
Study Summary
This study will target patients with gastrointestinal (GI) malignancy who present to any of 4 Penn Medicine emergency departments (EDs) with intractable abdominal pain. We will offer eligible patients an erector spinae plane block (ESPB), a regional anesthesia technique which is already offered to such patients in the ED at the University of Pennsylvania Healthy System (UPHS), for their intractable abdominal pain. We will compare the outcomes of this prospective cohort of patients to a matched historical control of patients with GI malignancy who were treated in the ED during the same time period as recruitment, but who were not recruited to partake in the study and who were managed with standard of care. Opioid consumption as measured by total milligram morphine equivalents (MMEs) over a 24-hour period and hospital length of stay (LOS) will be compared between cohorts. Additionally, for the ESPB cohort, pain level pre/post ESPB, and functionality and satisfaction with pain management at 24 hours will also be examined.
Primary Outcome
We will track the amount of opioids consumed within 24 hours by patients who received the erector spinae plane block
Conditions Studied
Interventions
- PROCEDURE Erector Spinae Plane Block
Study Locations (4)
Pennsylvania
- Hospital of the University of Pennsylvania - Philadelphia
- Penn Presbyterian Medical Center - Philadelphia
- Pennsylvania Hospital - Philadelphia
- Hospital of the University of Pennsylvania -- Cedar Avenue - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2025-12-11 |
| Est. Completion | 2027-06-15 |
| Phase | NA |
What NCT07211386 shows while recruiting
NCT07211386 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 25 participants, a relatively small participant target, below the 43-participant average among 3 other Pain Control trials with a reported enrollment target (42% lower).
The record links to 2 conditions, with Pain Control appearing as the primary indexed condition, and to 1 intervention - of which Erector Spinae Plane Block is the first listed.
NCT07211386 reports a single indexed study location in Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT07211386 about?
NCT07211386 is a clinical study titled "The Erector Spinae Plane Block For Gastrointestinal Malignancy Pain Treatment (EGIPT)". This study will target patients with gastrointestinal (GI) malignancy who present to any of 4 Penn Medicine emergency departments (EDs) with intractable abdominal pain. We will offer eligible patients an erector spinae plane block (ESPB), a regional anesthesia technique which is already offered to s...
What is the current status of trial NCT07211386?
This trial is currently recruiting. It is a NA study. The enrollment target is 25 participants. The study started on 2025-12-11. Estimated completion is 2027-06-15.
What conditions does trial NCT07211386 study?
This clinical trial studies the following conditions: Pain Control, Gastrointestinal Malignancy.
What interventions are being tested in trial NCT07211386?
The interventions under investigation include: Erector Spinae Plane Block (PROCEDURE).
Who is sponsoring clinical trial NCT07211386?
This trial is sponsored by Abramson Cancer Center at Penn Medicine, which has 402 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07211386 being conducted?
This trial has 4 study locations across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pain Control
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01166854 · 25 participants
Characterization of Familial Myopathy and Paget Disease of Bone
- NCT01913106 · 25 participants · Phase 1
HSV-tk + Valacyclovir Therapy in Combination With Brachytherapy for Recurrent Prostate Cancer
- NCT02138669 · 25 participants · NA
Intacs Prescription Inserts for Keratoconus Patients
- NCT02174549 · 25 participants · Phase 1
Dose-defining Study of Tirapazamine Combined With Embolization in Liver Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI